News

Almirall secures 5th partnership
Enlarge image

BusinessSpainItaly

Almirall secures 5th partnership

15.10.2012 - Patients in Australia and New Zealand will also receive Almirall's Aclidinium against the lung disease COPD. Invida is the licensing partner.

After the approval of Aclidinium by the European Commission in July and the following deal with Italian Menarini Group to commercialise the drug in most of Europe in July, Barcelona-based Almirall S.A. has inked a marketing partnership with Invida Holdings Private Limited, a member of the Menarini Group, to sell the drug on the fifth continent . Invida gains the commercial rights for Aclidinium in Australia and New Zealand, with the deal including both monotherapy and combination therapy (with Formoterol). Both treatments work against Chronic Obstructive Pulmonary Disease (COPD), where the drug relieves the tension in the muscles around the lungs to improve airflow.

COPD makes breathing difficult and is often caused by cigarette smoking. It is estimated that around 2 million people in Australia suffer from the disease, where it is the sixth most common cause of death among men and seventh among women, Almirall said. Financial details of the agreement have not been disclosed.  Eduardo Sanchiz, Chief Executive Officer of Almirall, states: "Together with Invida, we will be able to offer this novel therapy in Australia and New Zealand for COPD. With this new agreement Aclidinium, via partners or Almirall's own salesforce, now has access to over 80% of the COPD world market including the US, Japan, Korea and Europe, where we already have secured four license agreements in total." In Germany and Denmark, Aclidinium bromide is already on the market. It works as a long-acting inhaled muscarinic antagonist - sometimes referred to as an anticholinergic -, which has a long residence time at M3 receptors and a shorter residence time at M2 receptors. It is designed to be rapidly broken down in plasma into two major inactive metabolites, explaining its high topical efficacy but low propensity for systemic anticholinergic effects. When taken by inhalation, Aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction.   

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/almirall-secures-5th-partnership.html

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%
  • ADDEX3.10 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%

TOP

  • CO.DON3.32 EUR32.8%
  • EPIGENOMICS3.83 EUR23.5%
  • PAION3.05 EUR23.0%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-15.5%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 20.09.2014